Sudipto Mukherjee
Overview
Explore the profile of Sudipto Mukherjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wuliji N, Jones S, Gooley T, Gerds A, Medeiros B, Shami P, et al.
Blood
. 2025 Mar;
PMID: 40067123
Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown. We examined associations of SDOH with...
2.
Pierson S, Brandstadter J, Torigian D, Bagg A, Lechowicz M, Alapat MD D, et al.
Blood Adv
. 2025 Feb;
PMID: 39951615
Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the two forms of CD with unknown...
3.
Jabbour E, Oehler V, Koller P, Jamy O, Lomaia E, Hunter A, et al.
JAMA Oncol
. 2024 Nov;
11(1):28-35.
PMID: 39570620
Importance: Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant or intolerant to BCR-ABL1 tyrosine kinase inhibitors (TKIs) have limited treatment options. Olverembatinib, which is...
4.
Kewan T, Bahaj W, Gurnari C, Ogbue O, Mukherjee S, Advani A, et al.
Leukemia
. 2024 Jul;
38(9):2032-2036.
PMID: 39020062
No abstract available.
5.
Franklin M, Shupo F, Wayi-Wayi G, Zibelnik N, Jones E, Mason N, et al.
Oncol Ther
. 2024 Jul;
12(3):491-508.
PMID: 39012413
Introduction: Idiopathic multicentric Castleman disease (iMCD) is a rare, chronic, debilitating lymphoproliferative disorder where the mainstay of treatment is symptom management. Our recent international patient survey showed that patients with...
6.
Garcia-Manero G, Matsuno R, McBride A, Mohammed H, Idryo D, Broome R, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jun;
24(9):e283-e292.
PMID: 38871557
Introduction: Real-world studies of lower-risk myelodysplastic syndromes (LR-MDS) are limited. We evaluated treatment patterns, clinical outcomes, and healthcare resource utilization (HCRU) among patients with LR-MDS treated with erythropoiesis-stimulating agents (ESAs)...
7.
Shah S, Kundu R, Mishra R, Mukherjee S, Singh A
Leuk Res Rep
. 2024 Apr;
21:100456.
PMID: 38572397
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a rare and aggressive leukemia. Philadelphia chromosome-positive cytogenetic abnormality is most common in CML. It is difficult to differentiate between de novo Ph+ T-ALL/LBL...
8.
Mukherjee S, Brown-Bickerstaff C, Falkenstein A, Makinde A, Bland E, Laney J, et al.
Hemasphere
. 2024 Mar;
8(1):e38.
PMID: 38434524
No abstract available.
9.
Mukherjee S, Shupo F, Wayi-Wayi G, Zibelnik N, Jones E, Mason N, et al.
EClinicalMedicine
. 2023 Sep;
64:102192.
PMID: 37727459
Background: Idiopathic Multicentric Castleman Disease (iMCD) is a rare inflammatory lymphoproliferative disorder with heterogenous clinical presentations. The symptomatology in iMCD patients remains poorly understood. The aim of this study was...
10.
Vikram A, Chawla A, Mukherjee S
Int J Numer Method Biomed Eng
. 2023 Aug;
39(12):e3768.
PMID: 37605360
This study focuses on evaluating the response of the Total Human Model for Safety™ lower extremity finite element model under blast loading. Biofidelity of the lower extremity model was evaluated...